论文部分内容阅读
Over the last decades,the development of novel cancer therapeutics is often plagued by discrepancies between drug efficacies obtained in preclinical studies and outcomes of clinical trials.The inconsistencies can be partial attributed to a lack of clinical relevance of the cancer model for drug testing.